The UK’s statutory scheme revision for branded medicines
by Giuliana Miglierini The amendment of the statutory schemeregulating the increase in pricing and consequent clawback payments of…
UK will participate to European research programmes
by Giuliana Miglierini The divergent road opened as a consequence of the Brexit, in January 2021, between the…
The new MHRA’s framework for clinical studies
By Giuliana Miglierini The repositioning of the United Kingdom as a global leader for clinical development of medicinal…
Some perspectives on green pharmaceuticals
by Giuliana Miglierini The central role the green agenda plays within the EU Commission’s transformative policies impacts also…
A golden era for UK’s life sciences and a new Code of practice for its pharmaceutical industry
by Giuliana Miglierini Less than a year has gone since the Brexit, and the UK innovation landscape is…